New immune drug targets liver tumors in advanced cancer trial
NCT ID NCT05286814
Summary
This study is testing whether adding a new immune-stimulating drug called PDS01ADC to a specialized liver cancer treatment can better control advanced cancers that have spread to the liver. The treatment involves surgically placing a pump that delivers chemotherapy directly to the liver, combined with the new drug and standard chemotherapy. Researchers aim to see if this combination is more effective for adults with metastatic colorectal cancer, bile duct cancer, or adrenal gland cancer that is primarily in the liver.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.